AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7883414 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 28
Study 2889460 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg orally once daily
Number of subjects: 9
Study 2889460 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 400 mg orally once daily
Number of subjects: 9
Study 2889460 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 600 mg orally once daily
Number of subjects: 9
Study 2889460 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (all doses)
Number of subjects: 9
Study 29544720 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of morphine (M100)
Number of subjects: 40
Study 29544720 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of morphine (M200)
Number of subjects: 40
Study 26988367 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention
Number of subjects: 80
Study 23404669 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (a series of eight classes targeting the coparenting relationship)
Number of subjects: 169
Study 23404669 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 169
Study 22890714 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in older sedentary individuals (OS)
Number of subjects: 24
Study 22890714 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in older active individuals (OA)
Number of subjects: 24
Study 22890714 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in young sedentary individuals (Y)
Number of subjects: 24
Study 22890714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercise at 12 W in older sedentary individuals (OS)
Number of subjects: 24
Study 22890714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong physical activity in older active individuals (OA)
Number of subjects: 24
Study 20135144 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray bottle (SB)
Number of subjects: 7
Study 20135144 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study 18056004 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF from day 6 after induction chemotherapy
Number of subjects: 66
Study 18056004 — intervention group
Group type: COMPARATOR
Intervention: G-CSF from day 12 after induction chemotherapy
Number of subjects: 66
Study 16260969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (Bi)
Number of subjects: 16
Study 16260969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16
Study 12127639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of 40 mg PGF2alpha
Number of subjects: 100
Study 12127639 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal application of 200 mcg misoprostol (12 hourly doses, max 4 doses)
Number of subjects: 100
Study 7572582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 25 mg
Number of subjects: 126
Study 7572582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 126
Study 7572582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 126
Study 7572582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 126
Study 7572582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 2144618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Wright Peak Flow Meter
Number of subjects: 1566
Study 2144618 — intervention group
Group type: COMPARATOR
Intervention: Spirometer
Number of subjects: 1566
Study 630793 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 100 mg with concurrent lithium therapy (900 mg/day for 7 days)
Number of subjects: 0
Study 630793 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ) 100 mg without concurrent lithium therapy
Number of subjects: 0
Study 30700408 — intervention group
Group type: EXPERIMENTAL
Intervention: Scribes
Number of subjects: 88
Study 30700408 — intervention group
Group type: COMPARATOR
Intervention: Non-scribed shifts
Number of subjects: 88
Study 28233424 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (sulfonylurea)
Number of subjects: 747
Study 27130927 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health
Number of subjects: 546
Study 27130927 — intervention group
Group type: COMPARATOR
Intervention: Regular school PE activities
Number of subjects: 546
Study 23838763 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring
Number of subjects: 0
Study 23838763 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital flooring
Number of subjects: 0
Study 21851587 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electronic games
Number of subjects: 30
Study 21851587 — intervention group
Group type: COMPARATOR
Intervention: No active electronic games
Number of subjects: 30
Study 19624698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (oral health promotion programme)
Number of subjects: 1358
Study 19624698 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1358
Study 17270678 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually impaired individuals (binocular acuity less than 6/18)
Number of subjects: 13900
Study 17270678 — intervention group
Group type: COMPARATOR
Intervention: People with good vision
Number of subjects: 13900
Study 15093884 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1232
Study 11691667 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeless
Number of subjects: 252
Study 11691667 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 252
Study 9660419 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard long protocol of SC leuprolide acetate (group L)
Number of subjects: 60
Study 9660419 — intervention group
Group type: COMPARATOR
Intervention: Monthly injection of leuprolide acetate depot for 4 months (group D)
Number of subjects: 60
Study 9660419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L and D)
Number of subjects: 60
Study 8005563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) low dose (50 mg at 22 h)
Number of subjects: 10
Study 8005563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) high dose (50 mg at 8 h plus 100 mg at 22 h)
Number of subjects: 10
Study 8005563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 2801097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens drain
Number of subjects: 72
Study 2801097 — intervention group
Group type: COMPARATOR
Intervention: Donaldson drain
Number of subjects: 72
Study 805388 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg per day
Number of subjects: 0
Study 31603293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity skeletal muscle mass index (LESMI) measured volumetrically and cross-sectionally
Number of subjects: 100
Study 31603293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional single-slice CT measurements
Number of subjects: 100
Study 31603293 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability of cross-sectional slice segmentation
Number of subjects: 100
Study 28314551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain presence in fatigued patients with type 1 diabetes
Number of subjects: 120
Study 28314551 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle, joint and back pain, and headache
Number of subjects: 120
Study 28314551 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patients with pain vs. without pain
Number of subjects: 120
Study 28314551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and fatigue severity
Number of subjects: 120
Study 28314551 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of pain
Number of subjects: 120
Study 25691361 — intervention group
Group type: EXPERIMENTAL
Intervention: Models of survivorship care proposed and described in eight articles.
Number of subjects: 14
Study 25691361 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship models of care reported in six articles.
Number of subjects: 14
Study 25691361 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 23254227 — intervention group
Group type: EXPERIMENTAL
Intervention: MET+CBT+CM(Abstinence)
Number of subjects: 215
Study 23254227 — intervention group
Group type: EXPERIMENTAL
Intervention: MET+CBT+CM(Homework)
Number of subjects: 215
Study 23254227 — intervention group
Group type: COMPARATOR
Intervention: CaseM
Number of subjects: 215
Study 21911864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (80% VO2max)
Number of subjects: 12
Study 21911864 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60% VO2max)
Number of subjects: 12
Study 21911864 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40% VO2max)
Number of subjects: 12
Study 21911864 — intervention group
Group type: COMPARATOR
Intervention: Control (rest for 30 min)
Number of subjects: 12
Study 19706911 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus albendazole
Number of subjects: 104
Study 19706911 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 104
Study 16434669 — intervention group
Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate
Number of subjects: 0
Study 16434669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15379794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet with Soffban skin protection
Number of subjects: 150
Study 15379794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet with Atlantech skin protection drape
Number of subjects: 150
Study 15379794 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet without skin protection
Number of subjects: 150
Study 11422755 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (average 74 mg/day, range 12.5 to 125 mg/day)
Number of subjects: 32
Study 11422755 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with captopril)
Number of subjects: 32
Study 8996291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticlopidine (antiplatelet therapy)
Number of subjects: 123
Study 8996291 — intervention group
Group type: COMPARATOR
Intervention: Intense anticoagulant therapy (control)
Number of subjects: 123
Study 7949904 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminders for cervical cancer screening
Number of subjects: 3
Study 7949904 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminders for tetanus immunization
Number of subjects: 3
Study 3399330 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular stimulation by one shadow
Number of subjects: 52
Study 3399330 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular stimulation by two shadows
Number of subjects: 52
Study 3399330 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular stimulation by two shadows
Number of subjects: 52
Study 31977833 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy gel ingestion every 30 minutes (T1)
Number of subjects: 10
Study 31977833 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy gel ingestion every 45 minutes (T2)
Number of subjects: 10
Study 31977833 — intervention group
Group type: COMPARATOR
Intervention: No gel ingested during exercise (T3)
Number of subjects: 10
Study 30698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 82
Study 30698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 82
Study 30698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 82
Study 30698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 82
Study 30698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body muscle strength at baseline
Number of subjects: 82
Study 27847244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-body stretch with scapular stabilization
Number of subjects: 20
Study 27847244 — intervention group
Group type: COMPARATOR
Intervention: Cross-body stretch without scapular stabilization
Number of subjects: 20
Study 25319120 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg once a day for 3 months, then 50 mg twice a day
Number of subjects: 156
Study 25319120 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 156
Study 25319120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 23165696 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 523
Study 23165696 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1800 mg
Number of subjects: 523
Study 23165696 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 2400 mg
Number of subjects: 523
Study 23165696 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 3000 mg
Number of subjects: 523
Study 23165696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 21035362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 4mg/kg
Number of subjects: 141
Study 21035362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2mg/kg
Number of subjects: 141
Study 21035362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 18469255 — intervention group
Group type: EXPERIMENTAL
Intervention: Daidzein-7-O-beta-d-glucoside (DG) (1 mg DAI aglycone equivalent/kg body weight)
Number of subjects: 7
Study 18469255 — intervention group
Group type: COMPARATOR
Intervention: Daidzein (DAI) (1 mg DAI aglycone equivalent/kg body weight)
Number of subjects: 7
Study 16410347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study 16410347 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 12587824 — intervention group
Group type: EXPERIMENTAL
Intervention: High avidity anti-dsDNA antibodies in SLE patients
Number of subjects: 101
Study 12587824 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renal involvement
Number of subjects: 101
Study 12587824 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA method for anti-dsDNA antibody avidity determination
Number of subjects: 101
Study 12587824 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLAM activity index score
Number of subjects: 101
Study 11173719 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 177
Study 11173719 — intervention group
Group type: COMPARATOR
Intervention: Human insulin 30/70
Number of subjects: 177
Study 9417494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite treatment over a period of 28 days
Number of subjects: 40
Study 8338056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD) repeated every 21 days
Number of subjects: 45
Study 8338056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD)
Number of subjects: 45
Study 8338056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD) followed by modified radical mastectomy or radiotherapy
Number of subjects: 45
Study 3552076 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3 regimen (7 days of cytosine arabinoside and 3 days of daunorubicin)
Number of subjects: 0
Study 3552076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen (addition of 6‐thioguanine or extension of cytosine arabinoside to 10 days)
Number of subjects: 0
Study 3552076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole antibacterial prophylaxis during remission induction phase
Number of subjects: 0
Study 3552076 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue all treatment after 8 months of maintenance chemotherapy
Number of subjects: 0
Study 3552076 — intervention group
Group type: COMPARATOR
Intervention: Continue maintenance therapy for a total of 3 years
Number of subjects: 0
Study 3552076 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue all therapy at 8 months
Number of subjects: 0
Study 29234954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume (20-25 μl)
Number of subjects: 236
Study 29234954 — intervention group
Group type: COMPARATOR
Intervention: High volume (40-45 μl)
Number of subjects: 236
Study 27032107 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 46
Study 25595508 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study 25595508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25595508 — intervention group
Group type: COMPARATOR
Intervention: Staff unblinding
Number of subjects: 30
Study 25595508 — intervention group
Group type: COMPARATOR
Intervention: Staff identification of treatment device
Number of subjects: 30
Study 23389554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training
Number of subjects: 24
Study 23389554 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea
Number of subjects: 24
Study 23389554 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry (placebo)
Number of subjects: 24
Study 20591499 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val158 genotype (Val homozygote)
Number of subjects: 161
Study 20591499 — intervention group
Group type: COMPARATOR
Intervention: COMT Met homozygote genotype
Number of subjects: 161
Study 20591499 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT genotype (Val and Met)
Number of subjects: 161
Study 18714150 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (8 g/day for 16 weeks)
Number of subjects: 78
Study 17361594 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (wavelength 904 nm, frequency 4000 Hz, at dose 2J per point); TENS (frequency 80 Hz, 30 minutes, pulse duration 200 micros); exercise; conventional therapy with NSAIDs (meloxicam, 15 mg per day)
Number of subjects: 60
Study 17361594 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam (15 mg per day)
Number of subjects: 60
Study 12958684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure at 10 mmHg
Number of subjects: 24
Study 12958684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure at 15 mmHg
Number of subjects: 24
Study 11071328 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg daily, subcutaneously for the first 10 postoperative days)
Number of subjects: 43
Study 11071328 — intervention group
Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 43
Study 11071328 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (in 20 patients with total tube drainage)
Number of subjects: 43
Study 11071328 — intervention group
Group type: COMPARATOR
Intervention: Control (in 20 patients with total tube drainage)
Number of subjects: 43
Study 11071328 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (during postoperative days 6-10)
Number of subjects: 43
Study 11071328 — intervention group
Group type: COMPARATOR
Intervention: Control (during postoperative days 11-15)
Number of subjects: 43
Study 8636179 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA-cups
Number of subjects: 120
Study 8636179 — intervention group
Group type: COMPARATOR
Intervention: RM-polyethylene cups
Number of subjects: 120
Study 1418029 — intervention group
Group type: EXPERIMENTAL
Intervention: IX 800 mg
Number of subjects: 60
Study 1418029 — intervention group
Group type: EXPERIMENTAL
Intervention: IX 1,200 mg
Number of subjects: 60
Study 1418029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6388801 — intervention group
Group type: EXPERIMENTAL
Intervention: Three MOPP cycles before irradiation
Number of subjects: 121
Study 6388801 — intervention group
Group type: COMPARATOR
Intervention: Six MOPP cycles before irradiation
Number of subjects: 121
Study 31798713 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral cholecalciferol [2,000 IU per day] (experimental group)
Number of subjects: 42
Study 31798713 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without supplementation (control group)
Number of subjects: 42
Study 30282391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds, followed by lidocaine and normal saline injection.
Number of subjects: 134
Study 30282391 — intervention group
Group type: COMPARATOR
Intervention: Nerve block treatment with 1.4 mL of a mixture of dexamethasone and lidocaine after 360 seconds of sham PRF treatment, followed by 0.5 mL of normal saline.
Number of subjects: 134
Study 30282391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRF) treatment.
Number of subjects: 134
Study 30282391 — intervention group
Group type: COMPARATOR
Intervention: Nerve block treatment.
Number of subjects: 134
Study 26701831 — intervention group
Group type: EXPERIMENTAL
Intervention: PumpTune settings
Number of subjects: 22
Study 26701831 — intervention group
Group type: COMPARATOR
Intervention: Clinician settings
Number of subjects: 22
Study 26701831 — intervention group
Group type: EXPERIMENTAL
Intervention: PumpTune settings and Clinician settings
Number of subjects: 22
Study 25015912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147
Study 25015912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaccades in two-response blocks
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades in two-response blocks
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow-cued saccades in two-response blocks
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-cued saccades in two-response blocks
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaccades with increased response alternatives (from two to six)
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow-cued saccades with increased response alternatives (from two to six)
Number of subjects: 0